Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

Table 4 Comparison of the diagnostic value among fibrosis-4 index, non-alcoholic fatty liver disease fibrosis score, aspartate aminotransferase to platelet ratio index, and body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes score in hepatitis B virus-metabolic associated fatty liver disease (group A) and pure metabolic associated fatty liver disease (group B) subgroups

	Cutoffs	AUROC		Accuracy, %		Sensitivity, %		Specificity, %		PPV, %		NPV, %
		A	B	A	B	A	B	A	B	A	B	A	B
FIB-4	1.05	0.738	0.658	67.7	56.9	74.8	55.6	62.7	57.1	58.2	19.2	78.2	87.5
	1.30			68.2	67.2	58.5	44.4	75.0	71.4	61.9	22.2	72.3	87.5
	1.45			68.5	70.7	54.4	22.2	78.3	79.6	63.5	16.7	71.2	84.8
	2.67			63.2	84.5	17.0	22.2	95.3	95.9	71.4	50.0	62.3	87.0
	3.25			63.5	86.2	13.6	22.2	98.1	98.0	83.3	66.7	62.1	87.3
NFS	-2.100	0.725	0.692	68.2	67.2	70.1	77.8	67.0	65.3	59.5	29.2	76.3	94.1
	-1.455			64.9	74.1	44.2	55.6	79.2	77.6	59.6	31.3	67.2	90.5
	0.676			60.4	84.5	4.1	11.1	99.5	98.0	85.7	50.0	59.9	85.7
APRI	0.42	0.671	0.633	59.3	51.7	81.6	77.8	43.9	46.9	50.2	21.2	77.5	92.0
	0.50			60.2	55.2	70.7	77.8	52.8	51.0	51.0	22.6	72.3	92.6
	1.50			61.0	77.6	23.1	11.1	87.3	89.8	55.7	16.7	62.1	84.6
BARD	2	0.609	0.644	63.0	74.1	42.2	33.3	77.4	81.6	56.4	25.0	65.9	87.0

APRI: Aspartate aminotransferase to platelet ratio index; AUROC: Area under the receiver operating characteristic curve; BARD: Body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes score; FIB-4: Fibrosis-4 index; NFS: Non-alcoholic fatty liver disease fibrosis score; NPV: Negative predictive value; PPV: Positive predictive value.